Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today
announces that it has filed a registration statement on Form F-1
(Registration Statement) with the United States (U.S.) Securities
and Exchange Commission (SEC) today (U.S. time) relating to a
proposed initial public offering (Offering) of its American
Depository Shares (ADSs), representing the Company’s ordinary
shares, in the U.S. Telix has applied to list the ADSs on the
Nasdaq Global Market under the symbol “TLX”.
The number of ordinary shares to be represented
by each ADS, the number of ADSs to be offered and the price per ADS
for the proposed Offering have not yet been determined. The
Offering is subject to market conditions, and there can be no
assurance as to whether or when the Offering may be completed.
Jefferies, Morgan Stanley, Truist Securities and
William Blair will act as joint book-running managers for the
proposed Offering.
The proposed Offering will be made only by means
of a prospectus under the U.S. Securities Act of 1933. Copies of
the preliminary prospectus, when available, may be obtained from:
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY 10022, by phone at (877) 821-7388,
or by email at prospectus_department@jefferies.com; Morgan Stanley
& Co. LLC, Attention: Prospectus Department, 180 Varick Street,
2nd Floor, New York, NY 10014 or by email at
prospectus@morganstanley.com; Truist Securities, Inc., Attention:
Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta,
GA 30326, by telephone at (800) 685-4786, or by email at
TruistSecurities.prospectus@Truist.com; or William Blair &
Company, L.L.C., Attention: Prospectus Department, 150 North
Riverside Plaza, Chicago, IL 60606; by phone at (800) 621-0687; or
by e-mail at prospectus@williamblair.com. Australian investors are
only eligible to invest under the prospectus if they are exempt
from disclosure (for example, as sophisticated or professional
investors) under the Corporations Act 2001 (Cth).
A Registration Statement relating to the
securities referred to herein has been filed with the SEC but has
not yet become effective. These securities may not be sold, nor may
offers to buy these securities be accepted, prior to the time the
Registration Statement becomes effective. This announcement does
not constitute an offer to sell or the solicitation of an offer to
buy securities in any jurisdiction, and shall not constitute an
offer, solicitation or sale in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of that
jurisdiction.
About Telix
Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on
the development and commercialisation of diagnostic and therapeutic
radiopharmaceuticals and associated medical devices. Telix is
headquartered in Melbourne, Australia, with international
operations in the United States, Europe (Belgium and Switzerland),
and Japan. Telix is developing a portfolio of clinical and
commercial stage products that aims to address significant unmet
medical needs in oncology and rare diseases. Telix is listed on the
Australian Securities Exchange (ASX: TLX).
Telix Investor Relations
Australia
Ms. Kyahn WilliamsonTelix Pharmaceuticals
LimitedSVP Investor Relations and Corporate CommunicationsEmail:
kyahn.williamson@telixpharma.com
United States
Lisa WilsonIn-Site CommunicationsEmail:
lwilson@insitecony.com
This announcement has been authorised for release by the Board
of Telix Pharmaceuticals Limited.
Legal Notices
The information contained in this announcement
is not intended to be an offer for subscription, invitation or
recommendation with respect to shares of Telix Pharmaceuticals
Limited (Telix) in any jurisdiction, including the United States.
No representation or warranty, express or implied, is made in
relation to the accuracy or completeness of the information
contained or opinions expressed in the course of this announcement.
The information contained in this announcement is subject to change
without notification.
This announcement may contain forward-looking
statements that relate to anticipated future events, financial
performance, plans, strategies or business developments.
Forward-looking statements can generally be identified by the use
of words such as “may”, “expect”, “intend”, “plan”, “estimate”,
“anticipate”, “outlook”, “forecast” and “guidance”, or other
similar words. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to differ
materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking
statements. Forward-looking statements are based on the Company’s
good-faith assumptions as to the financial, market, regulatory and
other risks and considerations that exist and affect the Company’s
business and operations in the future and there can be no assurance
that any of the assumptions will prove to be correct. In the
context of Telix’s business, forward-looking statements may
include, but are not limited to, statements about: the initiation,
timing, progress and results of Telix’s preclinical and clinical
studies, and Telix’s research and development programs; Telix’s
ability to advance product candidates into, enrol and successfully
complete, clinical studies, including multi-national clinical
trials; the timing or likelihood of regulatory filings and
approvals, manufacturing activities and product marketing
activities; the commercialisation of Telix’s product candidates, if
or when they have been approved; estimates of Telix’s expenses,
future revenues and capital requirements; Telix’s financial
performance; developments relating to Telix’s competitors and
industry; and the pricing and reimbursement of Telix’s product
candidates, if and after they have been approved. Telix’s actual
results, performance or achievements may be materially different
from those which may be expressed or implied by such statements,
and the differences may be adverse. Accordingly, you should not
place undue reliance on these forward-looking statements. You
should read this announcement together with our risk factors, as
disclosed in our most recently filed reports with the ASX or on our
website.
To the maximum extent permitted by law, Telix
disclaims any obligation or undertaking to publicly update or
revise any forward-looking statements contained in this
announcement, whether as a result of new information, future
developments or a change in expectations or assumptions.
©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®
and Illuccix® names and logos are trademarks of Telix
Pharmaceuticals Limited and its affiliates – all rights
reserved.